Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
William ShenKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-4394-7099
Hiroyuki KatoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-0655-1519
Qin XuKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-5860-8225
Eranga R BalasooriyaKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-5491-3089
Meng-Ju WuKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-6847-7065
Jinkai WanKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-6736-0332
Hiroshi KondoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-0001-9492
Saireudee ChaturantabutCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-0350-6974
Srivatsan RaghavanDepartment of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5374-9918
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.ORCID 0000-0002-5073-442X
Samarjit PatnaikNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.ORCID 0000-0002-4265-7620
Min ShenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.ORCID 0000-0002-8218-0433
Robin K KelleyDivision of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.ORCID 0000-0002-1984-2430
James M ClearyDepartment of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7213-3951
Michael S LawrenceKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-1307-459X
David E RootCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0001-5122-861X
Krushna C PatraKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-2386-6435
Vanessa S SilveiraKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-5633-9490
Cyril H BenesKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-8751-9707
Vikram DeshpandeKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-4230-9308
Dejan JuricKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-2983-7704
William R SellersDepartment of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3539-9803
Cristina R FerroneKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-6295-1085
Wilhelm HaasKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-8225-9099
Francisca VazquezCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-2857-4685
Gad GetzKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-0936-0753
Nabeel BardeesyKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-3867-0416
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.R01CA219670 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, WONG, KWOK KIN · 2018 to 2022
$3.4M
Functions of the LKB1 tumor suppressor in control in metabolism and epigenticsR01CA215498 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL · 2018 to 2022
$2.7M
Functions of mutant IDH in cholangiocarcinomaR01CA280085 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY · 2023 to 2026
$2.6M
Targeting FGFR Alterations in Gastroesophageal CancerR01CA294689 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NABEEL El-BARDEESY, Sandra Ryeom · 2024 to 2026
$2.1M
Investigating the molecular mechanisms of growth in GNAS mutant pancreatic cancer.R37CA272854 · NCI · UNIVERSITY OF CINCINNATI · PI Krushna Chandra Patra · 2022 to 2026
$1.8M
Understanding Mechanisms of Resistance to Anti-angiogenic TreatmentsR01CA160216 · NCI · HENRY FORD HEALTH SYSTEM · PI ARBAB, ALI SYED · 2012 to 2016
$1.8M
Regulation and targeting of tumor cell states and plasticity in pancreatic cancerK08CA260442 · NCI · DANA-FARBER CANCER INST · PI Srivatsan Raghavan · 2022 to 2026
$1.5M
Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignanciesR01CA292508 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY, Robert Thomas Manguso · 2025 to 2026
$1.4M
Exploiting metabolic reprogramming to target IDH1 mutated cholangiocarcinomaK99CA245194 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SHI, LEI · 2020 to 2021
$356k
Cholangiocarcinoma FoundationCholangiocarcinoma Foundation C2T2 Precision Oncology AwardDOD Peer Reviewed Cancer Research Program (PRCRP) CA160216DOD Peer Reviewed Cancer Research Program (PRCRP) CA210849National Cancer Institute (NCI) 1K99CA245194-01National Cancer Institute (NCI) 1R01CA280085-01National Cancer Institute (NCI) P50CA127003NCI NIH HHS K08 CA260442NCI NIH HHS K99 CA245194NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA160216NCI NIH HHS R01 CA215498NCI NIH HHS R01 CA219670NCI NIH HHS R01 CA280085NCI NIH HHS R01 CA292508NCI NIH HHS R01 CA294689NCI NIH HHS R37 CA272854TargetCancer Foundation TargetCancer Foundation Cholangiocarcinoma Cell Line Project
6 · The paper itself
Abstract
Biliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report integrative analysis of 63 BTC cell lines via multi-omics and genome-scale CRISPR screens. We identify widespread EGFR dependency in BTC, alongside dependencies selective to anatomic subtypes. Additionally, we delineate strategies to overcome therapeutic resistance, with combined EGFR inhibition potentiating targeting of KRAS-mutant and FGFR2 fusion-driven models and SHP2 inhibition effective in the latter context. Clustering RNA/protein expression and dependencies data revealed functional relationships transcending single-gene alterations, with biliary, squamous, or dual biliary/hepatocyte lineage signatures stratifying BTC models. These subtypes exhibit distinct dependency profiles-including cell fate transcription factors GRHL2, TP63, and HNF1B, respectively-and demonstrate prognostic significance in patient samples. Potential subtype-specific targetable vulnerabilities include integrinα3 and the detoxification enzyme UXS1. This cell line atlas reveals therapeutic targets in molecularly defined BTCs, unveils disease subtypes, and provides a resource for therapeutic development. SIGNIFICANCE: This integrative analysis of BTC cell lines defines the landscape of vulnerabilities across BTCs, stratifying distinct subtypes, and provides a key resource for studying disease heterogeneity. The findings highlight strategies for targeting BTCs with specific genomic alterations, as well as broader approaches based on shared molecular programs and essential pathways.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets. · full record | OpenQuestion